Cargando…

Dual inhibition of CDK4 and FYN leads to selective cell death in KRAS-mutant colorectal cancer

Detalles Bibliográficos
Autores principales:	Wang, Yan, Lin, Rongjie, Ling, Huan, Ke, Yuan, Zeng, Yangyang, Xiong, Yudi, Zhou, Qian, Zhou, Fuxiang, Zhou, Yunfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882822/ https://www.ncbi.nlm.nih.gov/pubmed/31815009 http://dx.doi.org/10.1038/s41392-019-0088-z

Ejemplares similares

Integrated analysis of long noncoding RNA associated‐competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma
por: Yin, Hang, et al.
Publicado: (2018)

Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity
por: Assani, Ganiou, et al.
Publicado: (2018)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
por: Lee, Michael S., et al.
Publicado: (2016)

A novel function for cyclin D1 as a transcriptional role in oncogenesis and tumor development by ChIP-Seq and RNA-Seq
por: Xiong, Yudi, et al.
Publicado: (2021)

Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report
por: Xiong, Yudi, et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer
por: Liu, Huashan, et al.
Publicado: (2023)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
por: Liu, Huashan, et al.
Publicado: (2021)

Role of TMPRSS4 Modulation in Breast Cancer Cell Proliferation
por: Assani, Ganiou, et al.
Publicado: (2019)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Fyn regeneration
por: Short, Ben
Publicado: (2012)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Zinc induces CDK5 activation and neuronal death through CDK5-Tyr15 phosphorylation in ischemic stroke
por: Tuo, Qing-Zhang, et al.
Publicado: (2018)

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
por: Padhye, Aparna, et al.
Publicado: (2021)

Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis
por: He, Zhongshi, et al.
Publicado: (2017)

Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines
por: Padmanabhan, Pranesh, et al.
Publicado: (2019)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
por: Wang, Dan, et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

The Src-Kinase Fyn is Required for Cocaine-Associated Memory Through Regulation of Tau
por: Li, Hongchun, et al.
Publicado: (2022)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022)

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
por: Liu, Ke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_snjieprkubbte3tpfgfqvslc65